Cargando…
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
OBJECTIVE: Gaucher disease (GD) is a lysosomal storage disease characterized by a deficiency of glucocerebrosidase. Although enzyme‐replacement and substrate‐reduction therapies are available, their efficacies in treating the neurological manifestations of GD are negligible. Pharmacological chaperon...
Autores principales: | Narita, Aya, Shirai, Kentarou, Itamura, Shinji, Matsuda, Atsue, Ishihara, Akiko, Matsushita, Kumi, Fukuda, Chisako, Kubota, Norika, Takayama, Rumiko, Shigematsu, Hideo, Hayashi, Anri, Kumada, Tomohiro, Yuge, Kotaro, Watanabe, Yoriko, Kosugi, Saori, Nishida, Hiroshi, Kimura, Yukiko, Endo, Yusuke, Higaki, Katsumi, Nanba, Eiji, Nishimura, Yoko, Tamasaki, Akiko, Togawa, Masami, Saito, Yoshiaki, Maegaki, Yoshihiro, Ohno, Kousaku, Suzuki, Yoshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774255/ https://www.ncbi.nlm.nih.gov/pubmed/27042680 http://dx.doi.org/10.1002/acn3.292 |
Ejemplares similares
-
Abnormal pupillary light reflex with chromatic pupillometry in Gaucher disease
por: Narita, Aya, et al.
Publicado: (2014) -
In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
por: Ciana, Giovanni, et al.
Publicado: (2020) -
The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020) -
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022) -
Use of Ambroxol as Therapy for Gaucher Disease
por: Zhan, Xia, et al.
Publicado: (2023)